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Translation of remote control regenerative technologies for
bone repair
Hareklea Markides1, Jane S. McLaren2, Neil D. Telling1, Noura Alom2, E’atelaf A. Al-Mutheffer1, Richard O. C. Oreffo3,
Andrew Zannettino4, Brigitte E. Scammell5, Lisa J. White 6 and Alicia J. El Haj1
The role of biomechanical stimuli, or mechanotransduction, in normal bone homeostasis and repair is understood to facilitate
effective osteogenesis of mesenchymal stem cells (MSCs) in vitro. Mechanotransduction has been integrated into a multitude of
in vitro bone tissue engineering strategies and provides an effective means of controlling cell behaviour towards therapeutic
outcomes. However, the delivery of mechanical stimuli to exogenous MSC populations, post implantation, poses a signiﬁcant
translational hurdle. Here, we describe an innovative bio-magnetic strategy, MICA, where magnetic nanoparticles (MNPs) are used
to remotely deliver mechanical stimuli to the mechano-receptor, TREK-1, resulting in activation and downstream signalling via an
external magnetic array. In these studies, we have translated MICA to a pre-clinical ovine model of bone injury to evaluate
functional bone repair. We describe the development of a magnetic array capable of in vivo MNP manipulation and subsequent
osteogenesis at equivalent ﬁeld strengths in vitro. We further demonstrate that the viability of MICA-activated MSCs in vivo is
unaffected 48 h post implantation. We present evidence to support early accelerated repair and preliminary enhanced bone growth
in MICA-activated defects within individuals compared to internal controls. The variability in donor responses to MICA-activation
was evaluated in vitro revealing that donors with poor osteogenic potential were most improved by MICA-activation. Our results
demonstrate a clear relationship between responders to MICA in vitro and in vivo. These unique experiments offer exciting clinical
applications for cell-based therapies as a practical in vivo source of dynamic loading, in real-time, in the absence of pharmacological
agents.
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INTRODUCTION
Large skeletal defects resulting from trauma, tumour resection and
disease, remain a largely unresolved clinical problem, requiring a
bone tissue engineering solution.1–3 Typically, with standard
clinical intervention, the repair of a bone injury is achieved within
6 weeks owing to the highly efﬁcient repair mechanisms involved
in fracture healing. However, in 10% of all cases in which the
volume of bone loss is signiﬁcant, an inadequate bone healing
response leads to the formation of a non-union or segmental
defect.4–6 This condition represents a signiﬁcant clinical challenge
affecting people of all ages with substantial socio-economic
implications in terms of treatment and hospital costs.7,8 While
autologous bone grafts are considered the gold standard to
address the issue of non-union fractions, there remain associated
limitations leading to the development of alternative stem cell-
based or regenerative medicine therapies.1,5,9,10
Bone homeostasis, remodelling and fracture repair mechanisms
are regulated by a process known as mechanotransduction, the
conversion of physical forces acting on a cell to internal
biochemical signals.6,11–14 Despite the many published in vitro
studies identifying the need for mechanical conditioning of
osteoblasts and their mesenchymal stem cell (MSC) precursors
to drive osteogenesis and tissue maturation, few technologies
have been successfully translated into pre-clinical studies of bone
repair. While whole body rehabilitation programmes are routinely
prescribed in a clinical setting, a technology of clinical human
relevance which can translate physical stimuli into biological
responses in a controlled and localised fashion has, to date, not
been achieved. As such, mechanical stimuli are often lacking in
stem cell-based therapeutic approaches for bone regeneration.9,13
This can impede stem cell differentiation in vivo and ultimately
tissue synthesis, with a signiﬁcant impact on the quality and
quantity of bone formed thus affecting the clinical outcome of the
treatment.13
We have developed a pioneering bio-magnetic technology
(MICA; Magnetic Ion Channel Activation) designed to remotely
deliver directed mechanical stimuli to individual cells in culture or
within the body, to promote osteogenesis.15–17 By targeting
speciﬁc mechano-sensitive ion channels on the cell membrane of
MSCs with functionalised, biocompatible, magnetic nanoparticles
(MNPs), the opening of the ion channel can be controlled with an
oscillating external magnetic ﬁeld. The movement of the particle
creates a pico-newton force that is transferred to the ion channel
to which the MNPs have attached, propagating the mechanical
stimulus via mechanotransduction pathways inside the cell.15–18
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One such mechano-sensitive ion channel is TREK-1, a potassium
channel whose function is to maintain membrane potential and
plays a critical role in the mechanotransduction signalling
pathways in bone.17
In our earlier in vitro studies, we demonstrated using an
electrophysiological patch clamping model that we could open
and activate the 6 His tagged TREK-1 channel expressed in the
membrane of cells using remote mechanical movement of Ni2+
labelled MNPs.17 Importantly, these studies demonstrated the
speciﬁcity of this technique as no TREK-1 channel activation was
observed when MNPs were coated with RGD (Arg–Gly–Asp)
peptide, or when magnetic ﬁelds were applied in the absence of
MNPs. Furthermore, we went on to demonstrate that we could
deliver forces in the region of 8–15 pN onto the membrane
channels using remotely controlled MNPs which lead to the
differentiation of bone marrow-derived stromal stem cells
in vitro.15 We have generated further proof of concept data
showing activation of the TREK-1 ion channel in 2D models of
osteogenesis,15 3D cell-seeded constructs in vitro, and ex vivo
bone tissue engineering models.13 Our preliminary study in a
small animal model, showed controlled differentiation of bone
marrow stromal stem cells in hydrogel capsules implanted
subcutaneously in the dorsal region of nude mice.19
This manuscript describes the translation of this technology to a
relevant pre-clinical ovine bone defect model to explore the
therapeutic potential of MICA for bone repair. Our aim is to
demonstrate the relevance of MICA technology for use as a clinical
therapy, and a potential solution for the control of therapeutic
donor cells in regenerative medicine applications. In addition, we
consider the individual variation in responses between sheep
donors to further understand “good” and “poor” responders
within an ovine population.
RESULTS
STRO-4 positive oMSCs from all donors demonstrate tri-lineage
differentiation capacity
STRO-4 positive oMSCs (ovine mesenchymal stem cells) were
characterised by their ability to undergo osteogenic, adipogenic
and chondrogenic differentiation. Cells from all 12 donors
(experiment 2, Table 1) were successfully differentiated towards
all three lineages with marked donor dependent variation (Fig.1a).
Donors with lower osteogenic potential displayed an enhanced
osteogenic response after MICA technology application in vitro
The response of each set of donor oMSCs (donors 1–11,
experiment 2, Table 1) to MICA activation was assessed in a 3D
collagen hydrogel culture system. Variable mineralisation levels
were observed across donors exposed to an osteogenic environ-
ment and to MICA activation. Donors displaying low mineralisa-
tion levels in the static groups exhibited signiﬁcantly enhanced
osteogenesis following MICA activation (P < 0.001) (donors 1, 4, 11,
10, 6, 2, 9; Fig. 1b) with the fold-change increase ranging from 0.5-
fold (donor 5) to 25-fold (donor 2). Donors with a stronger
osteogenic response in static conditions were not inﬂuenced by
MICA activation to the same extent (donors 3; P < 0.05, donor 8;
ns). Finally, a key ﬁnding relevant to this study was that only donor
7 demonstrated a slight, but signiﬁcantly negative response to
MICA activation (P < 0.05). This data is supported by the density
maps of each gel demonstrating regions of high density
mineralisation as red (Fig. 1c).
Design and development of the magnetic array for in vivo MICA
activation
A vital component of this study was the development of a
magnetic array compatible with the ovine model to enable
activation of cells post-implantation. The external magnetic ﬁeld
strength required to activate MNP-labelled cells once implanted
within the femoral condyle defect was determined in vitro using a
HEK-293 NFK-β luciferase reporter cell line. Although greatest
activation was achieved at the highest ﬁeld strength, 2.55 KG
(Kilogauss), cells stimulated with weaker ﬁelds (0.92, 0.56, 0.32,
0.13 KG) continued to demonstrate signiﬁcantly enhanced activa-
tion compared to the static controls, albeit at reduced levels
(Fig. 2a). The minimum magnetic ﬁeld strength required for in vivo
MICA activation was thus determined to be 0.13 KG. Downstream
osteogenesis at ﬁeld strengths 0.13 KG and 2.55 KG was validated
in 2D monolayer cell cultures (Fig. 2b). This resulted in improved
mineralisation in all MICA activated groups (Fig. 2c), as seen by the
signiﬁcant increase in the number of bony nodules produced
compared to control groups (unlabelled and static condition)
regardless of ﬁeld strength (Fig. 2b, c). The schematic (Fig. 2d)
represents the size and orientation of the femoral defect relative
to the position of the magnetic array, deﬁning the maximum
working distance as 2.5 cm (“x” Fig. 2d).
Collectively, these data informed the primary design parameters
of the array and were taken forward to fabricate six permanent
magnetic arrays featuring magnets of varying dimensions and
shapes (Fig. 2e). Arrays were validated against the primary design
parameters, identifying arrays 1 and 4 as the only candidates
capable of generating a ﬁeld strength of 0.13 KG at 2.5 cm (Fig. 2f).
Array 4 was selected for subsequent in vivo ovine studies. Two
magnets were inserted into the aluminium frame with adjacent
alternating poles to generate the ﬁeld gradient required for MNP
manipulation (Fig. 2g). Accelerometers were used to determine
when sheep were most active as the changing magnetic ﬁeld
gradient was achieved with the movement of the sheep leg (Fig.
2h). Through monitoring the activity of 3 sheep over 7 days, 2
periods of increased activity were observed; 08:00–11:00 and
15:00–18:00 (Fig. 2h). Arrays were placed in a pouch ﬁtted around
the back legs of each sheep corresponding to the location of the
defect (Fig. 2i) and worn in hours of peak activity.
Surgical model
Surgery was tolerated well by all sheep without complications. No
signs of adverse reactions to the ECM (extracellular matrix)
hydrogel or MNP delivery were observed. C-reactive protein (CRP)
levels were measured 2 days’ post implantation (experiment 1,
Table 1; data not shown) revealing no deviation from baseline
Table 1. Experimental groups
Group Cells MNPs Magnet DiI stain Number of
defect
Time point
Experiment 1; Effect of MICA treatment on in vivo cell fate
1 (MICA) + + + Yes 6 2 days
2 + + − Yes 6 2 days
3 + − + Yes 6 2 days
4 + − − Yes 6 2 days
Experiment 2; Effect of MICA treatment on bone repair
1 (MICA) + + + No 6 13 weeks
2 + + − No 6 13 weeks
3 + − + No 6 13 weeks
4 + − − No 6 13 weeks
5 (ECM carrier
alone)
− − − No 6 13 weeks
6 (BG) Bone
graft
− − − No 6 13 weeks
7 (E) Empty − − − No 6 13 weeks
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levels. After an initial adjustment period, animals appeared to
tolerate the magnet truss well with no irritation of the fresh
wound and, importantly, no impaired mobility.
ECM construct remains intact and 50% of cells remain viable
2 days after implantation
The short-term fate of delivered oMSCs and the impact of MICA
activation on cell viability and construct integrity was assessed in
experiment 1 (Table 1). Constructs were extracted fully intact (Fig.
3a i) 48 h post-implantation with CM-DiI labelled oMSCs
(implanted oMSCs) clearly visible throughout (red ﬂuorescence)
(Fig. 3a, ii). An increase in construct stiffness was observed post-
harvest when compared to in vitro controls, with the general size
remaining wholly unchanged (6.4 ± 40.68 × 14.83 ± 1.2 mm) when
compared to pre-implanted standard dimensions (8 × 15mm).
Lactate dehydrogenase (LDH) is an enzyme present in all living
cells responsible for catalysing the reaction resulting in the blue
staining of viable CM-DiI labelled cells (Fig. 3b). Quantiﬁcation of
LDH stained cells (Fig. 3c) revealed an approximate 50% loss in cell
viability (P < 0.001) across all groups compared to the correspond-
ing in vitro control, with no inﬂuence of MNP-labelling nor MICA
activation.
Fig. 1 In vitro assessment of donor cell differentiation potential. a Comparative tri-lineage differentiation of STRO-4 positive ovine
mesenchymal stem cells (oMSCs) from 12 sheep donors. Images are presented in order of increasing differentiation potential for a, i
Osteogenesis at day 28 (Alizarin Red staining) with corresponding a, ii Adipogenesis at day 14 (Oil Red O staining), a, iii Chondrogenesis at day
21 (Alcian Blue staining) and compared to a representative proliferation media control (n= 3), scale bars; 100 µm. b Quantiﬁcation of in vitro
donor response to MICA activation in 3D collagen hydrogel cultures assessed by Micro-CT at day 28 and compared to static controls. Data
represents the average percentage mineralisation for donors 1–11 ± S.D. (n= 9). c Corresponding 2D slices showing mineralisation (red
regions) representing the central slice of the 3D hydrogel. Scale bar; 1 mm. Statistical signiﬁcance is represented by *P < 0.05, ***P < 0.001 and
ns is no signiﬁcance
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MICA treatment enhances early bone formation
Bone growth was evaluated by micro-CT at 13 weeks as an
indication of early repair. To account for donor-dependent
responses and eliminate biological variation, data was assessed
on an individual sheep basis (Fig. 4a). This was achieved by
comparing bone volume in the left and right defects of the same
sheep and expressing this as a percentage change in bone
volume. In this way, the effectiveness of two independent
treatments can be assessed in the same animal which has been
treated with an identical population of autologous cells. MICA
treated defects repaired to a greater degree in comparison to the
control defect of the same animal in ﬁve out of six sheep (Fig. 4a),
with donor 7 identiﬁed as the non-responder. When grouped, an
average improvement of 25 ± 6.5% is detected in MICA treated
animals by excluding the single non-responder, donor 7 (P < 0.05)
(Fig. 4b), and by 17.8 ± 8.9% by including donor 7 (Fig. 4c)
compared to the non-MICA animals. In comparison, sheep treated
either with a MICA-control group or the ECM carrier alone in both
legs demonstrated little differences in the degree of repair
Fig. 2 Design and development of a magnetic array for in vivo MICA activation. a Determining the minimum magnetic ﬁeld strength required
for cell activation. MICA activation of MNP-labelled HEK-293 NFΚ-β reporter cells at increasing magnetic ﬁeld strengths (corresponding to a
decrease in distance between cells and the magnetic array). Data represents the mean luminescence (RLU) ± SEM (n= 3). b MICA activation of
MNP-labelled and unlabelled STRO-4 positive ovine mesenchymal stem cells (oMSCs) towards osteogenesis (Alizarin red staining) in 6-well
monolayer cell culture plates at a ﬁeld strength of 0.13 and 2.55 KG and compared to static and unlabelled controls (n= 3), scale bar; 1 cm. c
Quantiﬁcation of bony nodules generated in monolayer as a result of MICA activation at either ﬁeld strength (0.13 and 2.55 KG) and compared
to static and unlabelled controls. Data represents the average number of visible bone nodules across 3 wells of a 6-well plate. d Schematic
representing the size and location of the defect within the femoral condyle relative to the position of the magnetic array. “X” marks the
location of MNP-labelled cells furthest away from the magnet i.e 2.5 cm in the ovine model. e Fabrication of six magnetic arrays containing
neodymium iron boron magnets of varying dimensions. f Comparative magnetic ﬁeld strength from arrays 1–6 at a distance of 2.5 cm. Data
represents the average magnetic ﬁeld strength at six random points on each magnet per array ± S.D. Red dashed line represents minimum
magnetic ﬁeld strength (0.13 KG) required to activate cells. g 3D Magnetic proﬁle of array 4 at a distance of 0.5 cm demonstrating alternating
poles. h Accelerometer data for sheep donors 4, 6 and 12 highlighting most active periods (red boxes) within a 24 h period. i Picture of a
sheep ﬁtted with the adapted truss housing magnetic array 4 within the pouch corresponding to the location of the defect. Statistical
signiﬁcance is represented by *P < 0.05, ***P < 0.001 and ns is no signiﬁcance
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between the two defects (6.5 ± 5.8% difference for non-MICA
sheep and 6.1 ± 5.4% difference for ECM carrier control sheep).
This data is supported visually by micro-CT images of defects
from the same sheep, where greater bone growth is observed in
the proximal (top) and peripheral (side) regions in MICA treated
defects compared to the contralateral MICA-control defect of the
same donor for donors 3, 5, 6, 8, and 10 but not for donor 7 (Fig.
4d). The gold standard treatment for large skeletal defects is
typically autologous bone graft, which was used as the positive
control in this study. In this short term study, this treatment group
where autologous bone is implanted to ﬁll the site can be seen to
completely occupy the defect with autograft and autologous
remodelled bone (Fig. 4e; donor 16L). Finally, bone growth is seen
in all groups originating at the boundaries of the defect with new
bone growth evident as regions of high density bone that is not
seen in day 2 scans (Fig. 4f). Finally, considering the average
population response, we demonstrate an increase in total new
bone formation in MICA treated defects compared to non-MICA
control groups (Fig. 5b), signiﬁcant only when donor 7 is excluded
(P < 0.05) (Fig. 5a).
Good correlation between in vitro and in vivo donor response to
MICA activation
Tracking the individual responses within the sheep enabled us to
identify correlations between the good responders and the poor
responders in vitro and in vivo. We observed a clear correlation
(R2= 0.7072; Fig.5c) between the in vitro performance (assessed
as percentage change in mineralisation relative to the correspond-
ing static control; Fig. 1b) and the in vivo bone ﬁll (calculated as
percentage change in bone ﬁll relative to the non-MICA control
leg of the same sheep; Fig. 4a) in this study.
Bone of greater maturity is observed in MICA treated defects with
enhanced recruitment of endogenous cells
Implanted constructs were not present at 13 weeks, with evidence
of new bone structures visible in all groups. Differences in the
amount, distribution and maturity of new bone was observed
between donors and treatment groups (Fig. 6a). Although
peripheral (side) bone growth from the surrounding trabeculae
was observed in all groups (Fig. 6a, i), evidence of bone extensions
across the defects was present only in the MICA group (Donor 3L;
Fig. 6a, i) and lacking in the contralateral MICA-control defect
(Donor 3R; Fig. 6a, i). Evidence of bone growth was also observed
in non-MICA animals (Donor 12; Fig. 6a, i). Trabecular-like
architecture was again evident only in the MICA defect with
intense red osteoid staining surrounding new structural bone
indicative of maturing bone and active osteogenesis (Donor 3L;
Fig. 6a, i). Although complete union was not achieved over this
time period, bone marrow-like tissue was present within defects of
all groups, with collagen ﬁbres dispersed throughout this matrix in
all groups (Fig. 6a, ii). Toluidine blue staining highlighted the
presence of new woven bone which is prominent in all groups,
but higher intensity of staining was observed in MICA defects (Fig.
a, iv). A collagen rich soft tissue structure is present in the proximal
(top) region of each defect (Fig. 6a, iii) with immuno-histochemical
analysis revealing key bone extracellular matrix components,
osteocalcin (Fig. 6a, v) and osteopontin (Fig. 6a, vi), embedded
within this collagen structure. Furthermore, this region was found
to be rich in osteopontin-positive and osteocalcin-positive cells
suggesting the presence of functional osteoblasts and osteocytes
involved in bone remodelling. ALP immunohistochemistry again
revealed functional osteoblasts distributed within this region at a
greater cellular density in the MICA defects and was associated
with active remodelling (Fig. 6a, vii). Overall, greater cellular
Fig. 3 Assessment of oMSC fate 48 h post implantation. a, i Implanted ECM-constructs remained intact with a, ii delivered oMSCs (CM-DiI-
stained; red ﬂuorescence) visibly distributed throughout the implanted construct; scale bar; 2 mm. b Representative cryo-sectioned samples of
the extracted in vivo construct and time-point matched in vitro controls constructs. b, i Viable oMSCs were identiﬁed by a distinct blue stain
attributed to the LDH reaction. b, ii Implanted oMSCs were identiﬁed by red ﬂuorescent staining. b, iii Viability of delivered cells was therefore
determined by the co-localisation of blue and red-ﬂuorescent stains. c Quantiﬁcation of cellular viability for all in vivo groups (cells only, MICA
and cells+MNPs) and compared to time-point matched in vitro controls. Data is presented as the average viability (proportion of duel LDH:
DiI labelled cells relative to total DiI labelled cells) for 5 random sections where 10 independent FOVs were analysed per section for each
sample ± S.D (n= 6). Statistical signiﬁcance is represented by * where, ***P < 0.001 and ns is no signiﬁcance
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Fig. 4 Micro-CT evaluation of bone repair at 13 weeks. a Percentage change in bone growth between defects of the same animal (n= 1). b, c
Corresponding averaged percentage change for the same sheep (n= 6) either excluding or including donor 7, the non-responder
respectively. d Representative Micro-CT slices for all 6 MICA treated sheep (donors 3, 5, 6, 7, 8 and 10) comparing the left (L) and right (R)
defects of each sheep (MICA vs non-MICA) at 13 weeks. e Representative control groups include a non-MICA treated sheep (donor 11L & R), a
positive control (donor 16L; bone graft), the negative control (donor 16R; empty defect), a carrier control (donor 17L & R) and f micro-CT
images of a defect at day 2 treated either with MICA or non-MICA (cells+MNPs). White dotted box represents the analysed region of interest.
Red dotted box represents region corresponding to histological analysis. Statistical signiﬁcance is represented by *P < 0.05
Translation of remote control regenerative technologies
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density of osteopontin-positive cells were observed in the MICA-
treated defect (Donor 3L) compared to the contralateral defect
(Donor 3R) and to either defects of donor 12 in which a similar
cellular density was observed (Fig. 6a, v). Early signs of
remodelling were observed in this region with early structural
Haversian Canals (orange arrow) appearing to develop, lined by
osteoblasts (green arrow). Evidence of the remnant cartilaginous
tissue and hypertrophic chondrocytes (white arrows) were
observed in all groups including the ECM-carrier group (Fig. 6b).
Furthermore, mineralisation of the cartilaginous tissue within cell
based groups (MICA and cells only) appeared to have progressed
further than the ECM treatment alone with regions of greater
osteocalcin staining observed (Fig. 6b). Calciﬁed histological
sections demonstrate ﬁbrous capping in the proximal regions in
all groups (Fig. 6c). A large amount of callous was found at the
edges of all defects, except in the bone graft group. Signs of
osteons and osteocytes are present with borders of osteoblasts
and a visible osteoid layer at the interface between new bone and
ﬁbrous tissue.
DISCUSSION
We describe an innovative remote bio-magnetic activation
technique (MICA) which can be used to control the behaviour of
MSCs in clinical stem cell-based therapies. Using an early stage
pre-clinical ovine model, we show that targeted activation of the
TREK-1 ion channel, present in oMSCs, can lead to initial enhanced
repair in donor-matched controls. Evidence of early elevated new
bone formation and increased bone outgrowth across the defect
were observed in MICA-treated defects. Assessment of individual
sheep, using internal controls to eliminate variations in the base-
line levels of repair between sheep and donor stem cell behaviour,
allowed for assessment of the early effects of MICA on defect
repair and demonstrated a correlation in ‘good’ and ‘poor’
responders between in vitro and in vivo studies.
In recent years, MSCs have emerged as appealing therapeutic
agents in the development of skeletal stem cell-based therapies
and have demonstrated remarkable clinical potential. A limitation
with using MSCs in clinical scenarios is the availability and
expansion of these cells to therapeutic numbers. Typically, less
than 0.001% of the bone marrow’s cell population are char-
acterised as MSCs, therefore, efforts to enrich the proportion of
MSCs are under development. STRO-1 is a well-regarded cell
surface antigen used in the characterisation of human MSC
populations.20 Oreffo and colleagues have shown that by selecting
with STRO-1, it is possible to enrich the MSC population during cell
isolation.21 Further to this, Zannettino and coworkers22 have
developed and characterised an analogous ovine marker, STRO-4,
demonstrating efﬁcient enrichment of oMSCs and for this reason
implemented in the current study.
Despite advances, the active control of stem cell behaviour
remains a challenge once implanted in the body. Biomechanical
forces are important stimuli for inﬂuencing stem cell behaviour
and are known to have a profound effect on bone repair.23,24
Evidence of this is presented in the early work of Lanyon and
colleagues, where it was shown that mechanical loading above a
critical threshold resulted in signiﬁcant new bone formation in a
rat model.25 This has been further validated in a number of small
Fig. 5 Continuation of Micro-CT analysis. a, b Averaged total bone formation comparing MICA treatment to the contralateral MICA control
(non-MICA) for donors 3, 5, 6, 7, 8 and 10 either excluding or including donor 7 respectively. c Correlation of the in vitro and in vivo responses
to MICA activation for donors 3, 5, 6, 7, 8 and 10 when comparing the percentage in change in mineralisation relative to donor matched static
control and percentage change in bone ﬁll relative to the non-MICA contralateral control leg of the same animal respectively. Dotted lines
indicate the 95% conﬁdence band. Line of best ﬁt plotted with a R2 value of 0.7072
Translation of remote control regenerative technologies
H Markides et al.
7
Published in partnership with the Australian Regenerative Medicine Institute npj Regenerative Medicine (2018)  9 
and large animal models to better understand the mechanisms of
adaptation to mechanical loading in bone.26 Despite our under-
standing of how mechanics affect tissue remodelling and repair,
clinical translation of mechanical stimuli has not been fully
achieved in vivo at a cellular level. As such, implanted therapeutic
cells lack the crucial mechanical stimuli required to direct repair in
a physiological manner.27 This is largely attributed either to the
limited translational potential of in vitro mechanical conditioning
systems, concerns of direct mechanical loading causing further
damage to the injured bone or scaffold stress shielding.
Furthermore, recent data has shown that mechanical pre-
conditioning of cell-seeded constructs prior to implantation may
result in less integration and remodelling in the repair site.28 MICA
addresses this challenge by non-invasively applying pico-newton
Translation of remote control regenerative technologies
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forces directly to implanted MNP-labelled cells from outside the
body using an external magnetic array, thereby activating
mechanotransduction pathways. Furthermore, we demonstrate
in this study for the ﬁrst time that we can control stem cell
behaviour remotely through mechanical forces in a pre-clinical
animal model.
MNPs are versatile translational tools demonstrating value in
several biomedical applications including targeted gene/drug
delivery, magnetic hyperthermia and now in regenerative
medicine. MNPs have received FDA approval for use as
biocompatible MRI contrast agents enabling improved diagnostics
and treatment of orthopaedic injuries.29 MNPs beneﬁt from their
capacity for remote magnetic manipulation and therefore offer a
new source of cell control.30 Concerns of safety are at the forefront
of any MNP-based research. We have extensively investigated
stem cell health and behaviour following MNP labelling with a
range of MNPs demonstrating no adverse outcomes nor
secondary uptake at optimised doses.31,32 In our hands, the
viability and function of MSCs labelled with Nanomag revealed no
detectable long-term cytotoxicity either in vitro or in an in vivo
subcutaneous mouse model.19 What remains unknown is the
effect of MNP-labelling on cellular viability once implanted into
the harsh microenvironment of the injured site. Importantly, the
addition of the MNP label and the magnetic gradient did not elicit
further cell death beyond that seen in all experimental groups
(MNP-labelled and unlabelled cells). Limited survival rate at the
repair site has been documented in other studies and is a well-
accepted limitation of the of the cell therapy industry.33,34 Loss of
cell viability can be attributed to a number of factors including a
harsh inﬂammation environment, anoikis (lack of cell adhesion to
the ECM) and limited oxygen and nutrients levels, all creating a
hostile microenvironment leading to cell death.33,34 Our results,
showing a reduction in cell number at 2 days’ post implantation in
all groups, support these ﬁndings.34
Our results demonstrate initial enhanced bone repair in MICA
treated defects in ﬁve out of the six sheep when compared to the
internal MICA-control contralateral defect. Histological and
immuno-histochemical analysis may suggest that MICA leads to
bone of greater maturity and architecture. Defects from all groups
were shown to repair via the endochondral ossiﬁcation pathway
as can be seen by the glycosaminoglycan molecules labelled by
the toluidine blue stain.35 This closely mimics the developmental
pathways of bone responsible for long bones and axial skeletal
growth during embryogenesis. The developmental pathway
involves the initiation of a hypertrophic cartilage template which
subsequently undergoes mineralisation and remodelling to form
functional bone.36,37 Evidence of remnant cartilaginous tissue and
hypertrophic chondrocytes were observed in all groups with signs
of enhanced matrix mineralisation present in MSC groups. This
strongly suggests that the presence of exogenous MSCs work to
promote soft tissue callus mineralisation towards mature miner-
alised bone as determined by micro-CT analysis.38 In our ﬁndings,
we show initial evidence that remote dynamic loading of
implanted cells may further enhance maturation as seen by the
increase in ALP staining within the newly formed bone
extracellular matrix, with evidence of osteoid seams lining new
trabecular-like bone structures which are otherwise not present in
MICA-control defects.
A strong periosteal reaction was observed within all defects
from all groups. We hypothesize that MICA activation may further
enhance this reaction, with increased bone mass observed at the
proximal region of the defect resulting in bone outgrowth across
the defect in all MICA treated defects, including donor 7, the non-
responder. This region is rich in collagen, embedded with
osteopontin and osteocalcin proteins and home to a variety of
host cells including osteoblasts, osteoclasts, chondrocytes and
endogenous MSCs, all contributing to repair and remodelling. In
line with previous data generated in an ex vivo chick femur
model,13,39 we hypothesise that one potential mode for action for
MICA is through a paracrine effect initiating the secretion of
cytokines and soluble factors from exogenous delivered MSCs to
recruit and activate endogenous therapeutic cells.30 This assertion
was supported by the increase in alkaline phosphatase staining, a
marker of active remodelling, which may account for the new
bone detected within that region.
A time point of 13 weeks was chosen for this study to enable us
to investigate the early phases of repair in a bone injury defect
ovine model. The challenge at this early phase is taking into
account the biological variation present in multiple sheep donors.
Due to the low levels of growth in the repair site overall, the
inherent differences in donors was evident and inﬂuenced our
ability to show statistical signiﬁcance using overall mean bone
volume data (supplementary ﬁgure 2). To study this in more detail
and highlight the signiﬁcance of the study, we have chosen to
compare animals both individually and grouped using internal
controls for MICA in the contralateral defects. In addition, cell
efﬁcacy and variability between the donors is known to result in
variable animal responses. Finally, using the internal controls
ensures that matched donor cells are used for both experimental
and control groups.
The biggest challlenge faced in this study was translating the
underlying MICA technology to the ovine animal model in a
manner that is closly aligned to the in vitro bioreactor system
which generated the proof of concept data from Henstock13 and
Kanczler et al.19. The sole purpose of this bioreactor was to deliver
a deﬁned magnetic ﬁeld at an oscillation frequency of 1 Hz to
MNP-labelled cells in culture, using a permanent magnetic array
where cells are exposed to a maximum ﬁeld strength of
25mT.13,40 Achieving a similar ﬁeld strength in vivo was
problematic due to the increase in distance between the external
magnet and the site of injury correlating to an exponential
decrease in ﬁeld strength. By mimicking this scenario in vitro using
the MICA bioreactor, we were able to design a system compatible
with the ovine model to conﬁdently infer a force directly to MNP-
labelled MSCs and manipulate the TREK-1 ion channel for
downstream osteogenesis. These results can be translated to
human orthopaedic conditions in the future with advances in
electromagnetic technologies where penetration depths of
Fig. 6 Histological evaluation of repair at 13 weeks. a Representative images from; Donor 3 (MICA animal) treated with MICA (left defect) and
cells only (right defect) and Donor 12 (MICA-control animal) treated with cells only (left defect) and cells+magnet (right defect). Histological
staining; a, i Masson-Goldner trichrome staining identifying new bone callus in green, osteoid steams in red and focused on bone outgrowth
over the top of the defect and along the peripheral edges (inserts). a, ii and a, iii Picrosirius red staining of collagen rich structures in the
central and proximal regions of each defect respectively. a, iv Toluidine blue staining identifying cartilage-like tissues rich in proteoglycans
(indicative of bone growth via the endochondral ossiﬁcation route) in purple. a, v Osteocalcin a, vi osteopontin and a, vii ALP (alkaline
phosphatase) immuno-histochemical (IHC) staining at the proximal region of each defect. b Representative ECM-carrier, MICA and cell only
sections stained for Alcian blue and Osteocalcin IHC demonstrating areas of cartilage like tissue (Alcian blue) and areas of mineralised tissue
(osteocalcin). c Representative calciﬁed sections from each group stained with paragon and toluidine blue staining; new bone growth is
identiﬁed by light pink staining while ﬁbrous tissue is stained deep purple. Scale bar represents 500 µm (a, i, a, iii),100 µm (a, ii, a, iv, a, v, a, vi, a,
vii, b) or 1500 µm (c). Green arrow (OB); osteoblasts, orange arrow (HC); Haversian Canals, white arrows; hypertrophic chondrocytes, BM; Bone
marrow. For further information on the anatomical location of each section, please refer to supplementary information, Fig. 3
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greater than 2.5 cm can be achieved. Furthermore, customised
and tailor-made orthopaedic cuffs can be designed to house the
electromagnetic system and targeted to injuries of all sizes and
extremities.
We recognise that a limitation of this study was the lack of
control over magnet oscillation where reliance was placed on
animal activity to physically move the array. Despite efforts to
schedule stimulation periods at moments of peak animal activity,
this could not be standardised across sheep nor over the duration
of the study. This had further implications on stimulation times
where the decision to activate cells for a period of 3 h in vivo, as
opposed to the standard 1 h implemented in vitro, was taken to
account for animal rest periods ensuring that cells were stimulated
for at least 1 h in total. Further work is underway to deﬁne optimal
magnetic dosing in vivo and develop a suitable means of
controlling oscillation using a bandage across a repair site.
As the prospect of stem-cell based therapies begin to enter the
clinic, researchers and clinicians are encouraged to account for
variability in stem cell function within a given patient popula-
tion.41 The therapeutic potential of MSCs amongst patients has
been shown to vary signiﬁcantly in terms of growth kinetics and
differentiation potential with consequences on in vivo bone
healing.42 In line with studies by De Boer and coworkers,42 we not
only demonstrate donor dependent tri-lineage potential, but also
donor-dependent responses to biomechanical stimuli in vitro. A
striking outcome from this study, was the profound effect of MICA
activation on donors with low osteogenic potential in vitro and
the clear correlation between levels of responses between in vitro
and in vivo studies. Given that the pathogenesis of non-unions
can, in many cases, be related to impaired osteogenesis, this data
suggests that MICA-activation of autologous MSCs from non-
union patients could have a stronger osteogenic response leading
to improved clinical outcomes.43 This response is supported by
data published by Charoenpanich et al.,44 where uniaxial cyclic
tensile strain was shown to dramatically enhance osteogenesis of
human MSCs from osteoporotic patients compared to healthy
patients. Although more work is required to further investigate
this theory, we present the potential to incorporate a mechanism
for dynamic loading into orthopaedic stem cells therapies and
improve outcomes.
MICA further beneﬁts from having a completely aligned in vitro
system which could potentially be used to develop a predictive
assay to determine “good” and “poor” responders prior to
treatment. Whilst the predictive element of this technology was
not incorporated into the design of the current study, the strong
correlation between the in vitro response of oMSCs to MICA
activation and ultimate in vivo bone repair for the same sheep
supports the use of this approach as a predictive assay. For
example, the only donor which responded poorly to MICA
activation in vitro was donor 7 which demonstrated an impaired
response to MICA in vivo as well. Also, donors 6 and 10
demonstrated greatest improvement in mineralisation as a result
of MICA activation in vitro and were similarly shown to perform
best in the in vivo study. Although this data is preliminary, it does
offer the possibility that MSCs from patients can be pre-screened
and, based on these results, the clinician could then deﬁne how
successful a MICA therapy would be for a patient. Further work is
required to fully validate this potential application.
In our short term pre-clinical model, we present evidence to
suggest that MICA technology can be used to augment and
control cell based therapies in this case for a potential wide array
of orthopaedic and other clinical applications. The MICA system
can be used to apply remote cell loading in a variety of cell-only
and cell-seeded scaffolds with varying degrees of stiffness. This
innovative approach enables cells within soft injectable hydrogels
to be loaded in situ following implantation, which has not
previously been possible due to the soft nature of the gels
rendering them incapable of withstanding mechanical loading.
Furthermore, from a regulatory standpoint, where one-step
surgical techniques are recommended, MICA can be adapted to
match such scenarios.45 Finally, considering future clinical
applications, our pre-clinical study supports the observation that
inter-individual variation needs to be considered to better design
human trials and predictive models.46
METHODS
Reagents were purchased from Sigma Aldrich, UK unless otherwise
speciﬁed.
Animal experiments
Methods were conducted in accordance to the UK Home Ofﬁce
Regulations and protocols approved by the University of Nottingham
Animal Welfare and Ethical Review Body. For all surgeries, animals were
placed in lateral recumbency to allow access to the sternum and medial
aspect of both hind legs.
Sheep. Nineteen healthy, English Mule ewes aged 2–4 years with a mean
weight of 77 kg were used and assigned randomly to each treatment
groups (Table 1). It should be noted that each sheep received a different
treatment in each leg.
Bone marrow harvest. Autologous MSCs were isolated by bone marrow
aspiration from the sternum of anesthetized animals using a 100mm 8
Gauge Jamshidi needle, (UK Medical Ltd., Shefﬁeld, UK). Aspirate was
collected in αMEM containing 10% FBS, 1% L-glutamine, 1% antibiotic and
anti-mycotic (AA) and heparin sodium to prevent clotting (5000 IU/ml,
Wockhardt, Wrexham, UK).
Defect. Three weeks post initial bone marrow harvest, a single cylindrical
defect (8 mm diameter × 15mm deep) was created in the cancellous bone
region of the medial femoral condyle in the left and right hind leg of each
animal. Throughout coring and reaming, the drills were cooled with sterile
saline solution to prevent tissue damage.
Cell delivery. Pre-set ECM constructs were immediately implanted within
the defect using the customised delivery device (supplementary data,
Fig. 1).
Sheep truss. Twenty four hour post defect surgery, sheep were ﬁtted with
the modiﬁed truss and either the magnetic array or the sham array aligned
to the location of the defect. Trusses were worn for 3 h/day, 5 days/week.
Sacriﬁce. Sheep were sacriﬁced either at 2 days (experiment 1) or
13 weeks (experiment 2) post-op by pentobarbital overdose administered
intravenously. The femoral condyles were retrieved immediately and
trimmed for further analysis (Micro-CT and histology). Samples were ﬁxed
in 10% neutral buffered formalin for 7 days before proceeding.
Selection of STRO-4 positive MSCs
The mononuclear cell fraction from each donor was isolated by red blood
cell (RBC) lysis treatment by initially ﬁltering the aspirate using a 100 µm
cell sieve and centrifuging (220 g; 30 min). The supernatant was carefully
removed, replaced with 2ml of ice cold RBC lysis buffer and incubated
(3min; RT) with gentle agitation. Lysis buffer was quenched with 45ml ice
cold PBS and lysed cells removed by centrifugation (220 g; 5 min). This
process was repeated until a white pellet appeared at which point 2 ml of
blocking buffer (αMEM, 10% rat serum, 1% bovine serum albumin (BSA)
and 5% FBS) was added to the pellet and incubated (30 min; 4 °C). Cells
were then washed with MACS buffer (PBS, 0.5% BSA and 2mM EDTA
disodium salt) and incubated with the STRO-4 IgG hybridoma (20 µg/ml;
Adelaide University) for 30min at 4 °C. Cells were again washed with MACS
buffer and incubated with 200 µl of the MACS anti-mouse IgG MicroBeads
(Miltenyi Biotec, UK) (30 min; 4 °C) prior to MACS separation using the LS
MACS column (Miltenyi Biotec, UK). STRO-4 oMSCs were collected and
plated in expansion media (αMEM media, 20% FBS, 1% L-Glutamine and
1% AA) and maintained at 37 °C for 1 week before further media changes.
STRO-4 positive oMSCs were cultured under standard cell culturing
conditions in αMEM (10% FBS, 1% L-glutamine and 1% AA).
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MNP labelling of STRO-4 positive oMSCs
Nanomag (Micromod, Germany), a commercially available 250 nm,
carboxyl-coated MNP was functionalised with a TREK-1 antibody (Alomone
Labs, APC-047, Israel) as described previously.13 To label oMSCs, cells at
80–90% conﬂuency were trypsinized, counted and washed in PBS to
remove any residual FBS. Cells were then re-suspended in serum free
media (SFM) and incubated with TREK-1 functionalised MNPs (1 mg/ml) at
a ratio of 25 µg MNPs per 106 cells with 1 µl DOTAP (1 µg/ml) (3 h; 37 °C).
The corresponding unlabelled cell groups were simultaneously incubated
in SFM only. Unbound MNPs were removed and cells washed in PBS by
centrifugation (1000 rpm; 5 min).
Encapsulation of oMSCs within a ECM gel construct for in vivo
delivery
Preparation of the ECM digest (12.5 mg/ml) is described in a previously
published article.47 In brief, 5 × 106 MNP labelled or unlabelled oMSCs from
each donor were re-suspended in a 20% HEPES solution (prepared in SFM)
and thoroughly mixed with the ECM digest at a ratio of 1:3 to achieve a
ﬁnal volume of 0.8 ml. The subsequent gel mixture was then transferred to
a customised sterile delivery device and allowed to set for 1 h at 37 °C
before hydrating with 500 µl SFM. Pre-set constructs were maintained at
37 °C and implanted the following day. Acellular constructs were prepared
in a similar manner.
In vitro donor response to MICA activation
Donor response to MICA activation was assessed in vitro using a collagen
hydrogel system previously reported.13 Here, 2.5 × 105 oMSCs (P3) from
each donor were encapsulated in 3.94mg/ml stock solution of rat tail type
1 collagen and neutralised with a 20% HEPES solution (prepared in SFM) to
a ﬁnal concentration of 2.5 mg/ml and volume of 300 µl. The collagen and
cell suspension was seeded into non-adherent 48-well plates and allowed
to set (1 h; 37 °C) before hydrating with 1 ml of osteogenic differentiation
media. Hydrogels were cultured for 28 days in osteogenic media with a
single media change per week. MICA groups consisted of MNP-labelled
cells and were stimulated for 1 h/day in the MICA bioreactor while the
static groups consisted of unlabelled cells and were maintained in identical
conditions without a magnetic ﬁeld. Mineralisation levels were evaluated
by micro-CT (micro-CT 50, Scanco, Switzerland) on day 28. Micro-CT scans
were performed with beam energy of 55 kVp, intensity of 145 µA, a 200ms
integration and spatial resolution of 10 µm.
Assessment of cellular viability by LDH staining
Construct preparation. ECM constructs were prepared as described above
and implanted immediately within the femoral defect. Donor matched
in vitro controls consisting of unlabelled oMSCs were simultaneously
prepared and maintained in culture for the duration of the study (2 days).
SFM in control groups was changed to expansion media at the time of
in vivo implantation.
Construct harvest. Implanted ECM constructs were harvested from the
defect of sacriﬁced sheep, transferred directly to expansion media to
maintain cell viability and transported on ice. Constructs (implanted and
in vitro controls) were embedded in optimum cutting temperature (OCT)
medium (VWR, UK) and frozen by immersing in liquid nitrogen cooled
isopentane and stored at −20 °C until cryosectioning (Bright, Clinicut
Clinical Cryostat).
LDH staining. Viable cells were identiﬁed post implantation by the
presence of the active LDH enzyme. Sections (16 µm) were incubated in a
staining solution consisting of 7.2 mg/dL NBT (nitro blue tetrazolium; Fisher
Scientiﬁc) and 60mg/dL NADH (β-Nicotinamide adenine dinucleotide
hydrate) prepared in 0.05 M TRIS buffer at pH 7.6. (30min; 37 °C). Unused
reagents were removed by a single water wash and then in ascending and
descending concentrations of acetone (30, 60, 90%). Slides were mounted
with Hydromout and imaged (Nikon Eclipse, Ti-S). Implanted cells were
identiﬁed by red ﬂuorescence (CM-DiI staining) and viable cells by blue
staining under bright ﬁeld settings. Ten random ﬁeld of views were imaged
per section in a total of ﬁve sections. Viability was evaluated by ImageJ by
quantifying the proportion of dual LDH and CM-DiI staining relative to total
CM-DiI staining.
Micro-computed tomography (Micro-CT) evaluation of bone repair
at 13 weeks
Bone growth was determined by micro-CT (Skyscan 1174, Skyscan,
Kontich, Belgium). Micro-CT scans were performed with beam energy of
50 kV, current of 800 µA, 0.50 µm aluminium ﬁlter and a voxel resolution of
32 µm. A threshold of 255/50 was selected to segment bone from
surrounding tissue and includes both mineralised bone and immature
bone. Transmission images were reconstructed using Skyscan supplied
software (NRecon) with the resulting 2D image representing a single 32 µm
slice (1/256).
Statistical analysis
GraphPad Prism 6.0 was used for all statistical assessments. In most cases,
data is presented as the average value ± standard deviation (S.D.) unless
otherwise stated. Figure 1b: In vitro donor response to MICA activation.
Signiﬁcance was determined by two-way ANOVA with a post hoc Sidaks
multiple comparison test (Alpha= 0.05). Figure 2a: Determining the
minimum magnetic ﬁeld strength required for cell activation. Data here,
represents the mean value ± SEM with signiﬁcance determined by one-
way ANOVA and a Dunnetts multiple comparison test (Alpha= 0.05).
Figure 2c: Quantiﬁcation of bony nodules. Signiﬁcance was determined by
one-way ANOVA with a post hoc Tukey test (Alpha= 0.05). Figure 3c:
Quantiﬁcation of cellular viability. Signiﬁcance was determined by one-way
ANOVA test with a post hoc Tukey test (Alpha= 0.05). Figure 4b, c:
Averaged percentage change in bone ﬁll. Data represents the average
percentage change in bone ﬁll ± SEM with signiﬁcance determined by a
one-way ANOVA with a post hoc Tukey test (Alpha 0.05). Figure 5a, b: Total
bone formation. Data represents the average total bone volume ± SEM
with signiﬁcance determined by a two-way paired t test. In all cases; *P <
0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 and ns is no signiﬁcance and
data is considered to be normally distributed except micro-CT data.
For further method detail please refer to the “Supplementary Methods”
section in supplementary information.
Data availability
The data sets generated during and/or analysed during the current study
are available from the corresponding author on reasonable request.
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